Pueraria mirifica and healthy aging
What 4 graded rows on pueraria mirifica agree on for healthy aging, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Pueraria mirifica page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Pueraria mirifica page, with its PubMed record.
Your question
Pueraria mirifica and healthy aging
4 rows · 246 peopleMostly an improvement: 3 of 4 rows, and most of the people. 1 had mixed results.
- CGrade C× 2
- DGrade D× 2
- Rows
- 4
- Trials
- 4
- People
- 246
What the rows share
From the rowsThe best-graded row, grade C, is a randomized trial of 63 people (2022) and found an improvement.
The rows run from 52 to 71 people, published from 2007 to 2022: 4 single studies.
The rows
3 improved · 1 mixed- CGrade CVaginal atrophy signs and vaginal blood flow (topical gel) · Improved
RCT · n 63 · 2022 · Postmenopausal women with genitourinary syndrome of menopause (Thailand)
Applied in the vagina (schedule not stated in the abstract) · 12 weeks
Vaginal artery pulsatility and resistance indices fell versus placebo; at week 12 the vaginal maturation index was higher (55.19 vs 20.29) and all vaginal health index items were better than with placebo.
Row on the Pueraria mirifica page · PubMed 35550707 (opens PubMed)
- DGrade DVaginal dryness and vaginal cell maturation · Improved
RCT · n 71 · 2007 · Healthy postmenopausal women aged 45–60
20, 30 or 50 mg/day · 24 weeks
Vaginal dryness fell after 12 weeks and the vaginal maturation index shifted toward mature cells; adverse effects did not differ from placebo.
Row on the Pueraria mirifica page · PubMed 17415017 (opens PubMed)
- DGrade DMenopausal symptom scores (25 vs 50 mg) · Improved
RCT · n 52 · 2011 · Women after hysterectomy with menopausal symptoms
25 or 50 mg/day · 6 months
Symptom scores fell similarly with both doses; there was no placebo group.
Row on the Pueraria mirifica page · PubMed 20872225 (opens PubMed)
- CGrade CBacterial vaginosis markers and genital symptoms (topical gel) · Mixed
RCT · n 60 · 2020 · Postmenopausal women with genitourinary syndrome of menopause (Thailand)
Applied in the vagina (schedule not stated in the abstract) · 12 weeks
Abnormal Nugent scores were less common with the gel (6.7% vs 23.3%) and the vaginal health index improved more, but genital symptoms did not improve more than with placebo.
Row on the Pueraria mirifica page · PubMed 32972635 (opens PubMed)